Tesco Pension Investment Ltd Purchases 17,195 Shares of PRA Health Sciences Inc (PRAH)
Tesco Pension Investment Ltd lifted its position in PRA Health Sciences Inc (NASDAQ:PRAH) by 4.9% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 365,634 shares of the medical research company’s stock after buying an additional 17,195 shares during the quarter. Tesco Pension Investment Ltd’s holdings in PRA Health Sciences were worth $40,326,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also recently made changes to their positions in PRAH. Motco grew its stake in shares of PRA Health Sciences by 937.0% in the 1st quarter. Motco now owns 280 shares of the medical research company’s stock valued at $31,000 after buying an additional 253 shares in the last quarter. Financial Gravity Wealth Inc. acquired a new stake in PRA Health Sciences in the 1st quarter worth approximately $53,000. CENTRAL TRUST Co lifted its holdings in PRA Health Sciences by 28.2% in the 1st quarter. CENTRAL TRUST Co now owns 842 shares of the medical research company’s stock worth $93,000 after purchasing an additional 185 shares during the last quarter. Enlightenment Research LLC acquired a new stake in PRA Health Sciences in the 4th quarter worth approximately $101,000. Finally, Carroll Financial Associates Inc. lifted its holdings in PRA Health Sciences by 7.6% in the 1st quarter. Carroll Financial Associates Inc. now owns 1,517 shares of the medical research company’s stock worth $167,000 after purchasing an additional 107 shares during the last quarter. 98.14% of the stock is owned by institutional investors and hedge funds.
PRAH has been the subject of several analyst reports. SunTrust Banks boosted their target price on PRA Health Sciences to $120.00 and gave the stock an “average” rating in a report on Monday, March 4th. BidaskClub upgraded PRA Health Sciences from a “hold” rating to a “buy” rating in a report on Friday, March 22nd. ValuEngine upgraded PRA Health Sciences from a “hold” rating to a “buy” rating in a report on Monday, February 4th. Robert W. Baird boosted their target price on PRA Health Sciences from $119.00 to $122.00 and gave the stock an “outperform” rating in a report on Thursday, February 28th. Finally, Mizuho set a $100.00 target price on PRA Health Sciences and gave the stock a “hold” rating in a report on Friday, May 3rd. One analyst has rated the stock with a sell rating, six have issued a hold rating and five have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $113.22.
PRA Health Sciences (NASDAQ:PRAH) last issued its quarterly earnings results on Wednesday, February 27th. The medical research company reported $1.21 EPS for the quarter, topping analysts’ consensus estimates of $1.18 by $0.03. PRA Health Sciences had a return on equity of 26.87% and a net margin of 5.50%. The company had revenue of $729.65 million during the quarter, compared to analyst estimates of $750.67 million. As a group, equities analysts predict that PRA Health Sciences Inc will post 4.63 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Tesco Pension Investment Ltd Purchases 17,195 Shares of PRA Health Sciences Inc (PRAH)” was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://www.watchlistnews.com/tesco-pension-investment-ltd-purchases-17195-shares-of-pra-health-sciences-inc-prah/3016907.html.
PRA Health Sciences Company Profile
PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.
Featured Article: Why do companies engage in swaps?
Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences Inc (NASDAQ:PRAH).
Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.